Results 1 to 10 of about 11,315 (180)
Hospital-based care for hallucinogens and risk of mania and bipolar disorder: A population-based cohort study. [PDF]
PLoS MedicineBackgroundHallucinogen use for both recreational and medical purposes is rapidly increasing globally, raising concerns about potential adverse effects.
Daniel T Myran +6 more
doaj +2 more sources
The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews [PDF]
Brain SciencesBackground: Substance use disorders (SUDs) are highly prevalent, affecting over 48.5 million Americans. Available treatments for SUD remain insufficient, and many patients do not respond to existing interventions despite adequate adherence to treatments.
Sabrina Correa da Costa +7 more
doaj +2 more sources
Pediatrics and Neonatology, 2023 Background: Infants exposed prenatally to drugs of substance use are at increased risk for seizures, strabismus, feeding difficulty, and neurodevelopmental delays. Exposed preterm infants may have additional morbidities related to prematurity.
Subhash Puthuraya +5 more
doaj +1 more source
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Frontiers in Psychiatry, 2021 Addressing global mental health is a major 21st-century challenge. Current treatments have recognized limitations; in this context, new ones that are prophylactic and effective across diagnostic boundaries would represent a major advance.
Rita Kočárová +5 more
doaj +1 more source
Therapeutic effect of psilocybin in addiction: A systematic review
Frontiers in Psychiatry, 2023 BackgroundPsychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SUDs).
Pim B. van der Meer +18 more
doaj +1 more source
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans
Molecules, 2021 Hallucinogens are a loosely defined group of compounds including LSD, N,N-dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences.
Paul Cumming +5 more
doaj +1 more source
Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002–2019
Addictive Behaviors Reports, 2022 Aims: Information on time trends in use of different plant-based hallucinogens is lacking. The current study used nationally representative U.S. data to assess overall and age-specific time trends in the prevalence of lifetime and 12-month use of plant ...
Claire A. Walsh +4 more
doaj +1 more source
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective
Frontiers in Psychiatry, 2021 Accumulating clinical evidence shows that psychedelic therapy, by synergistically combining psychopharmacology and psychological support, offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and/or maladaptive ...
John R. Kelly +16 more
doaj +1 more source
Candyflipping and Other Combinations: Identifying Drug–Drug Combinations from an Online Forum
Frontiers in Psychiatry, 2018 Novel psychoactive substances (NPS) refer to synthetic compounds or derivatives of more widely known substances of abuse that have emerged over the last two decades.
Michael Chary, David Yi, Alex F. Manini
doaj +1 more source
Addictive Behaviors Reports, 2019 Background: This study examined the prevalence of hallucinogen use in a large sample of university students and its associations with mental health issues.
Jon E. Grant +2 more
doaj +1 more source